Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | AGL | P35573 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25893834 | 0.86 | CHRNA7 (0.36) | CHRNA7DRD3SLC6A3ARG1 | |
| SCHEMBL16508763 | 0.84 | AGL (0.34) | AGLGNAI3GNAO1GNAI1GBA2 | |
| SCHEMBL17476073 | 0.81 | AGL (0.38) | ARG1AGLGBA2 | |
| SCHEMBL17476075 | 0.81 | AGL (0.38) | ARG1AGLGBA2 | |
| SCHEMBL17476076 | 0.81 | AGL (0.38) | ARG1AGLGBA2 | |
| SCHEMBL4378367 | 0.81 | CHRNA7 (0.33) | CHRNA7DRD3SLC6A3ARG1 | |
| SCHEMBL24745613 | 0.81 | ARG1 (0.33) | ARG1AGLGBA2 | |
| SCHEMBL14493190 | 0.80 | DPP4 (0.38) | ARG1DPP4GBA2 | |
| SCHEMBL26791035 | 0.80 | DPP4 (0.38) | ARG1DPP4GBA2 | |
| SCHEMBL15533712 | 0.76 | GLB1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2809156-B1 | ALLOSTERIC MODULATORS OF 5-HYDROXYTRYPTAMINE 2C RECEPTOR (5-HT2CR) | UNIV TEXAS (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9533973-B2 | Allosteric modulators of 5-hydroxytryptamine 2C receptor (5-HT2CR) | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-01-03 | — | — | US | disclosed |
| US-20140336375-A1 | ALLOSTERIC MODULATORS OF 5-HYDROXYTRYPTAMINE 2C RECEPTOR (5-HT2CR) | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-13 | — | — | US | disclosed |
| WO-2013086266-A2 | ALLOSTERIC MODULATORS OF 5-HYDROXYTRYPTAMINE 2C RECEPTOR (5-HT2CR) | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336375-A1 | ALLOSTERIC MODULATORS OF 5-HYDROXYTRYPTAMINE 2C RECEPTOR (5-HT2CR) | HTR2C, HTR2A, HTR3B | CHRNA7 134/4885DRD3 151/4885SLC6A3 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.